Coya Therapeutics, Inc. COYA

COYA Company Overview

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunomodulatory therapies for neurodegenerative, autoimmune, and metabolic diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on therapies designed to enhance regulatory T cell (Treg) function and reduce chronic inflammation. Its research and development efforts are primarily directed toward diseases characterized by immune dysfunction, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer’s disease, Parkinson’s disease, and other inflammatory conditions.

The company’s primary value drivers are its Treg-focused biologic and cell therapy platforms, including low-dose interleukin-2 (LD IL-2)–based approaches and combination immunotherapies intended to restore immune homeostasis. Coya Therapeutics has positioned itself within a specialized segment of immunology-focused neuroscience by targeting inflammatory pathways increasingly associated with neurodegeneration. Founded in 2020 and headquartered in Houston, Texas, the company became publicly traded on the NASDAQ under the ticker COYA following its initial public offering in 2023. Its evolution has centered on advancing translational immunology research into clinical-stage therapeutic candidates.